Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VanEck Semiconductor ETF (SMH) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
VanEck Semiconductor ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs VanEck Semiconductor ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while VanEck Semiconductor ETF trades at $584.53. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.

ACADSMH
Market Cap
$5.07B
Sector
Health
52-Week High
$29.41$668.91
52-Week Low
$20.06$286.43
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

VanEck Semiconductor ETF

SMH trades at $584.83, up 2.71% with a neutral technical signal. Moving averages show bullish momentum while oscillators indicate neutral conditions. Recent institutional activity includes Ferguson Shapiro's $4.53 million investment and Clark Asset Management's 105.8% stake increase. The ETF faces competition from alternative semiconductor funds like CHPY, which some analysts favor for income generation.

Outlook remains balanced with AI spending driving semiconductor demand but increasing competition and tariff risks. The fund's heavy Nvidia concentration presents both opportunity and volatility risk. Technical resistance at $587 could limit near-term gains while support at $560 provides downside protection.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About VanEck Semiconductor ETF

The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.

Read more on SMH